

Table 1: Questions addressed in this systematic review with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).

Questions addressed by this systematic review		
<ol style="list-style-type: none"> 1. What is the efficacy of TCZ in reducing the frequency and severity of FMF attacks? 2. What is the safety profile of TCZ in patients with FMF? 3. What is the optimal administration regimen of tocilizumab (TCZ) in FMF patients, and how does it affect treatment outcomes? 4. What are the gaps in the current evidence regarding the use of tocilizumab (TCZ) in FMF, and what further research is needed in this area? 5. Are there any particularities in pediatric patients? 		
Participants	Interventions	Comparisons
Patients diagnosed with FMF	TCZ therapy for the treatment of FMF	<ol style="list-style-type: none"> 1. To placebo or standard of care in randomized controlled trials (RCTs) 2. Different administration regimens of tocilizumab (e.g., intravenous vs. subcutaneous, frequency).
Main Outcomes		
<ol style="list-style-type: none"> 1. Frequency and severity of FMF attacks 2. Adverse events associated with TCZ therapy 3. Quality of life measures 4. Laboratory markers of inflammation (e.g., ESR, CRP levels) 5. Disease activity scores 6. Treatment adherence and patient satisfaction 		
Type of studies		
RCTs, observational studies, case-control studies, and case series reporting on the efficacy and safety of TCZ in FMF patients.		